NASDAQ
31.10.25 | 20:40
12,275 US-Dollar
+3,50 % +0,415
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 86 | GlobeNewswire (Europe) | ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors... ► Artikel lesen | |
| 07.08. | LENSAR, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | LENSAR: EPS verfehlt Schätzungen um 0,08 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 07.08. | LENSAR GAAP EPS of -$0.15, revenue of $13.94M | 1 | Seeking Alpha | ||
| 07.08. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | LENSAR, Inc.: LENSAR Reports Second Quarter 2025 Results and Provides Business Update | 151 | GlobeNewswire (Europe) | 18 ALLY Robotic Cataract Laser Systems ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total... ► Artikel lesen | |
| LENSAR Aktie jetzt für 0€ handeln | |||||
| 02.07. | LENSAR, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.07. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 108 | GlobeNewswire (Europe) | ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted... ► Artikel lesen | |
| 02.06. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 106 | GlobeNewswire (Europe) | ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted... ► Artikel lesen | |
| 27.05. | FTC Requests More Information on Alcon's $430 Million Acquisition of Lensar | 14 | CPI | ||
| 22.05. | LENSAR, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | LENSAR, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | LENSAR, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | LENSAR, Inc.: LENSAR Reports First Quarter 2025 Results and Provides Business Update | 235 | GlobeNewswire (Europe) | 14 ALLY Robotic Laser Cataract Systems ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first... ► Artikel lesen | |
| 24.03. | Alcon Agrees To Acquire LENSAR For Up To Approximately $430 Mln | 521 | AFX News | WASHINGTON (dpa-AFX) - Eye care company Alcon, Inc. (ALC) and medical technology company LENSAR, Inc. (LNSR) announced Monday the companies have entered into a definitive merger agreement through... ► Artikel lesen | |
| 24.03. | Alcon übernimmt Medtech-Unternehmen Lensar für bis zu 430 Millionen Dollar | 1.006 | Moneycab | Genf - Der Augenheilkundespezialist Alcon kauft in den USA zu. Für bis zu 430 Millionen Dollar übernimmt das Genfer Unternehmen das Medizintechnikunternehmen Lensar aus den USA. Lensar ist laut einer... ► Artikel lesen | |
| 24.03. | Alcon Agrees to Acquire LENSAR, Inc. | 459 | Business Wire | Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon's cataract equipment and technology portfolio Next generation technology will be expanded globally, improving the efficiency... ► Artikel lesen | |
| 04.03. | LENSAR, Inc.: LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 143 | GlobeNewswire (Europe) | ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors... ► Artikel lesen | |
| 27.02. | LENSAR, Inc.: LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update | 209 | GlobeNewswire (Europe) | 31 ALLY Robotic Cataract Laser Systems placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Announces Voting Results from Special Meeting of Stockholders / Evofem Shareholders Did Not Approve the Merger with Aditxt | -- Evofem Shareholders Did Not Approve the Merger with Aditxt --
-- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 16,870 | -1,75 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 33,040 | +0,76 % | BrightSpring Health Services GAAP EPS of $0.17 misses by $0.15, revenue of $3.33B misses by $20M | ||
| SIEMENS HEALTHINEERS | 48,630 | +0,12 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 46,420 | -0,30 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| FRESENIUS | 49,700 | -0,64 % | DEUTSCHE BANK RESEARCH stuft Fresenius SE auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Fresenius von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen. Die anstehenden Quartalszahlen des Medizinkonzerns... ► Artikel lesen | |
| GENEDX | 137,17 | +4,20 % | GeneDx raises 2025 revenue guidance to $428M amid accelerating exome and genome test growth | ||
| GERRESHEIMER | 27,280 | -1,16 % | Gerresheimer: Weitere Details - millionenschwere Fehlbuchung | Am Wochenende hat der Spezialverpackungshersteller Gerresheimer per Ad-Hoc-Mitteilung dem Kapitalmarkt weitere Details zur laufenden Prüfung problematischer Buchungen im Konzernbericht für das Fiskaljahr... ► Artikel lesen | |
| BUTTERFLY NETWORK | 2,695 | 0,00 % | Butterfly Network reaffirms $91M-$95M 2025 revenue target while accelerating AI and chip innovation | ||
| PROCEPT BIOROBOTICS | 34,040 | -1,02 % | PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance | SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| UNITEDHEALTH | 297,50 | +1,12 % | Earnings Preview - Teil 1: Make or Break für den Markt: Die Zahlen von UnitedHealth, Microsoft & Alphabet! | © Foto: Richard Drew/AP/dpaDiese in den kommenden Tagen (KW44) anstehenden US-Quartalszahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell eingepreisten Kursreaktionen... ► Artikel lesen | |
| BETA BIONICS | 27,210 | +1,61 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| PROGYNY | 18,690 | +0,27 % | Progyny, Inc.: Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause | Global employers can now empower their workforces with comprehensive women's health benefits, supported by localized expertiseNEW YORK, Oct. 22, 2025. (Nasdaq: PGNY), a global leader in women's health... ► Artikel lesen | |
| CLEARPOINT NEURO | 23,230 | -1,90 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles | SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,280 | -0,94 % | Privia Health Group, Inc. - 8-K, Current Report |
LENSAR INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 12,275 Euro und damit +3,50 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LENSAR INC finden Sie auf Wallstreet Online.